RxDoctor Payments Data

Joel Regalado

Acute Care · Ridgewood, NJNPI 1356579635

Payments from drug & device makers

$641in general payments, 2019–2025

Across 28 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$329
  • Astellas Pharma US Inc$150
  • Abiomed$66
  • Pfizer$49
  • Johnson & Johnson$17
  • Mindray DS USA, Inc.$15
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$49177%
  • Education$15023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie18$329
Astellas Pharma US Inc2$150
Abiomed2$66
Pfizer3$49
Johnson & Johnson1$17
Mindray DS USA, Inc.1$15
Shionogi Inc1$15

How this compares

$641 in reported general payments places this provider in the 65th percentile of 656 acute care providers in New Jersey.

See all acute care providers in New Jersey

Medicare billing

Part B allowed, 2024
$18,288
Medicare patients
81
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →